These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 31220253)

  • 1. Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome.
    McMacken GM; Spendiff S; Whittaker RG; O'Connor E; Howarth RM; Boczonadi V; Horvath R; Slater CR; Lochmüller H
    Hum Mol Genet; 2019 Jul; 28(14):2339-2351. PubMed ID: 31220253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure.
    Vanhaesebrouck AE; Webster R; Maxwell S; Rodriguez Cruz PM; Cossins J; Wickens J; Liu WW; Cetin H; Cheung J; Ramjattan H; Palace J; Beeson D
    Brain; 2019 Dec; 142(12):3713-3727. PubMed ID: 31633155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromuscular junction immaturity and muscle atrophy are hallmarks of the ColQ-deficient mouse, a model of congenital myasthenic syndrome with acetylcholinesterase deficiency.
    Sigoillot SM; Bourgeois F; Karmouch J; Molgó J; Dobbertin A; Chevalier C; Houlgatte R; Léger J; Legay C
    FASEB J; 2016 Jun; 30(6):2382-99. PubMed ID: 26993635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-2 Adrenergic Receptor Agonists Enhance AChR Clustering in C2C12 Myotubes: Implications for Therapy of Myasthenic Disorders.
    Clausen L; Cossins J; Beeson D
    J Neuromuscul Dis; 2018; 5(2):231-240. PubMed ID: 29865088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congenital myasthenic syndromes with acetylcholinesterase deficiency, the pathophysiological mechanisms.
    Legay C
    Ann N Y Acad Sci; 2018 Feb; 1413(1):104-110. PubMed ID: 29405353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis.
    Ohno K; Ito M; Kawakami Y; Krejci E; Engel AG
    Chem Biol Interact; 2013 Mar; 203(1):335-40. PubMed ID: 22981737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of salbutamol on neuromuscular junction function and structure in a mouse model of DOK7 congenital myasthenia.
    Webster RG; Vanhaesebrouck AE; Maxwell SE; Cossins JA; Liu W; Ueta R; Yamanashi Y; Beeson DMW
    Hum Mol Genet; 2020 Aug; 29(14):2325-2336. PubMed ID: 32543656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COLQ-Related Congenital Myasthenic Syndrome and Response to Salbutamol Therapy.
    Padmanabha H; Saini AG; Sankhyan N; Singhi P
    J Clin Neuromuscul Dis; 2017 Mar; 18(3):162-163. PubMed ID: 28221310
    [No Abstract]   [Full Text] [Related]  

  • 9. Developmental consequences of the ColQ/MuSK interactions.
    Karmouch J; Dobbertin A; Sigoillot S; Legay C
    Chem Biol Interact; 2013 Mar; 203(1):287-91. PubMed ID: 23089045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mouse model of the slow channel myasthenic syndrome: Neuromuscular physiology and effects of ephedrine treatment.
    Webster RG; Cossins J; Lashley D; Maxwell S; Liu WW; Wickens JR; Martinez-Martinez P; de Baets M; Beeson D
    Exp Neurol; 2013 Oct; 248():286-98. PubMed ID: 23797154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The beta-adrenergic agonist salbutamol modulates neuromuscular junction formation in zebrafish models of human myasthenic syndromes.
    McMacken G; Cox D; Roos A; Müller J; Whittaker R; Lochmüller H
    Hum Mol Genet; 2018 May; 27(9):1556-1564. PubMed ID: 29462491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological Treatments for Congenital Myasthenic Syndromes Caused by
    Shao S; Shi G; Bi FF; Huang K
    Curr Neuropharmacol; 2023; 21(7):1594-1605. PubMed ID: 36703579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein-anchoring strategy for delivering acetylcholinesterase to the neuromuscular junction.
    Ito M; Suzuki Y; Okada T; Fukudome T; Yoshimura T; Masuda A; Takeda S; Krejci E; Ohno K
    Mol Ther; 2012 Jul; 20(7):1384-92. PubMed ID: 22371845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction.
    Cartaud A; Strochlic L; Guerra M; Blanchard B; Lambergeon M; Krejci E; Cartaud J; Legay C
    J Cell Biol; 2004 May; 165(4):505-15. PubMed ID: 15159418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Collagen Q and anti-MuSK autoantibody competitively suppress agrin/LRP4/MuSK signaling.
    Otsuka K; Ito M; Ohkawara B; Masuda A; Kawakami Y; Sahashi K; Nishida H; Mabuchi N; Takano A; Engel AG; Ohno K
    Sci Rep; 2015 Sep; 5():13928. PubMed ID: 26355076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and molecular analysis of a novel COLQ missense mutation causing congenital myasthenic syndrome in a Syrian family.
    Matlik HN; Milhem RM; Saadeldin IY; Al-Jaibeji HS; Al-Gazali L; Ali BR
    Pediatr Neurol; 2014 Jul; 51(1):165-9. PubMed ID: 24938146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes.
    Mihaylova V; Müller JS; Vilchez JJ; Salih MA; Kabiraj MM; D'Amico A; Bertini E; Wölfle J; Schreiner F; Kurlemann G; Rasic VM; Siskova D; Colomer J; Herczegfalvi A; Fabriciova K; Weschke B; Scola R; Hoellen F; Schara U; Abicht A; Lochmüller H
    Brain; 2008 Mar; 131(Pt 3):747-59. PubMed ID: 18180250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synaptic basal lamina-associated congenital myasthenic syndromes.
    Maselli RA; Arredondo J; Ferns MJ; Wollmann RL
    Ann N Y Acad Sci; 2012 Dec; 1275():36-48. PubMed ID: 23278576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective Treatment With Albuterol in DOK7 Congenital Myasthenic Syndrome in Children.
    Tsao CY
    Pediatr Neurol; 2016 Jan; 54():85-7. PubMed ID: 26552645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Analysis of a Congenital Myasthenic Syndrome Due to a Pathogenic Variant Affecting the C-Terminus of ColQ.
    Barbeau S; Semprez F; Dobbertin A; Merriadec L; Roussange F; Eymard B; Sternberg D; Fournier E; Karasoy H; Martinat C; Legay C
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.